US angioplasty market braces for new stents
This article was originally published in Clinica
Executive Summary
The $450 million US angioplasty market could change radically in the next two years. The approval of second-generation stents will eat into Cordis' 95% share of the stent market and companies that offer a broad range of angioplasty products will be the favourites with the big healthcare providers. Lehman Brothers analysts Amelia McDonald and Jonathan Foster project 20% annual growth in the stent market for each of the next three years.